Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion

BMC Biotechnology

Volumn 12, Issue , 2012, Pages

  Liu, Mengyuan ^a   Huang, Yi ^a   Hu, Lei ^a,c   Liu, Guoping ^b   Hu, Xueping ^a   Liu, Dongxu ^a   Yang, Xiaosong ^a  

^a HUBEI UNIVERSITY   (China)

^b YANGTZE UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Fusion protein; Human serum albumin; Interleukin 1 receptor antagonist; Pharmacodynamic; Pharmacokinetics; Rheumatoid arthritis

Indexed keywords

BIODISTRIBUTIONS; CARBOXYL-TERMINAL; CLINICAL APPLICATION; COLLAGEN-INDUCED ARTHRITIS; CYTOKINES; FUSION PROTEINS; HUMAN SERUM ALBUMINS; IN-VIVO; INFLAMMATORY DISEASE; INTERLEUKIN-1; PICHIA PASTORIS; RECEPTOR ANTAGONISTS; RETENTION TIME; RHEUMATOID ARTHRITIS; TARGET TISSUES; THERAPEUTIC EFFICACY; THERAPEUTIC MOLECULES; UPTAKE RATE;

DRUG DELIVERY; MAMMALS; PHARMACODYNAMICS; PHARMACOKINETICS; RECOMBINANT PROTEINS; TISSUE;

DISEASES;

COLLAGEN; HUMAN SERUM ALBUMIN; HYBRID PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; FOREFOOT; KIDNEY; LIVER; LUNG; MOUSE; NONHUMAN; PICHIA PASTORIS; PLASMA HALF LIFE; RHEUMATOID ARTHRITIS; SPLEEN;

ANIMALS; ARTHRITIS, EXPERIMENTAL; HALF-LIFE; HUMANS; JOINTS; MALE; MICE; PICHIA; RECEPTORS, INTERLEUKIN-1; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN;

MUS; PICHIA PASTORIS;

EID: 84866548615     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-12-68     Document Type: Article

References (43)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003, 423(6937):356-361. 10.1038/nature01661, 12748655.
2. Schiff MH. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis 2000, 59(Suppl 1):i103-i108. 1766616, 11053099.
3. Niedermeier M, Pap T, Korb A. Therapeutic opportunities in fibroblasts in inflammatory arthritis. Best Pract Res Clin Rheumatol 2010, 24(4):527-540. 10.1016/j.berh.2010.02.002, 20732650.
4. Lee YR, Kweon SH, Kwon KB, Park JW, Yoon TR, Park BH. Inhibition of IL-1beta-mediated inflammatory responses by the IkappaB alpha super-repressor in human fibroblast-like synoviocytes. Biochem Biophys Res Commun 2010, 378(1):90-94.
5. Abramson S. Drug delivery in degenerative joint disease: where we are and where to go?. Adv Drug Deliv Rev 2006, 58(2):125-127. 10.1016/j.addr.2006.01.005, 16631277.
6. Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46(11):2838-2846. 10.1002/art.10578, 12428223.
7. Niu X, He D, Deng S, Li W, Xi Y, Xie C, Jiang T, Zhang JZ, Dong C, Chen G. Regulatory immune responses induced by IL-1 receptor antagonist in rheumatoid arthritis. Mol Immunol 2011, 49(1-2):290-296.
8. Goldbach-Mansky R. Blocking interleukin-1 in rheumatic diseases. Ann N Y Acad Sci 2009, 1182:111-123. 10.1111/j.1749-6632.2009.05159.x, 3080043, 20074280.
9. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004, 350(25):2591-2602. 10.1056/NEJMra040226, 15201416.
10. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009, 68(7):1100-1104. 10.1136/ard.2008.093690, 2689525, 19060002.
11. Thaler K, Chandiramani DV, Hansen RA, Gartlehner G. Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics 2009, 3:485-498. 2802074, 20054439.
12. Cunnane G, Madigan A, Murphy E, FitzGerald O, Bresnihan B. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford) 2001, 40(1):62-69.
13. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009, 68(1):25-32. 2596305, 18203761.
14. Kaiser C, Knight A, Nordstrom D, Pettersson T, Fransson J, Florin-Robertsson E, Pilstrom B. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int 2012, 32(2):295-299. 10.1007/s00296-011-2096-3, 3264859, 21881988.
15. Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, Anderson CL. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003, 197(3):315-322. 10.1084/jem.20021829, 2193842, 12566415.
16. Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry 2006, 45(15):4983-4990. 10.1021/bi052628y, 16605266.
17. Kragh-Hansen U, Chuang VT, Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 2002, 25(6):695-704. 10.1248/bpb.25.695, 12081132.
18. Elsadek B, Kratz F. Impact of albumin on drug delivery - New applications on the horizon. J Control Release 2011, 157(1):4-28.
19. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008, 132(3):171-183. 10.1016/j.jconrel.2008.05.010, 18582981.
20. Kratz F, Elsadek B. Clinical impact of serum proteins on drug delivery. J Control Release 2012, 161(2):429-445. 10.1016/j.jconrel.2011.11.028, 22155554.
21. Muller N, Schneider B, Pfizenmaier K, Wajant H. Superior serum half life of albumin tagged TNF ligands. Biochem Biophys Res Commun 2010, 396(4):793-799. 10.1016/j.bbrc.2010.04.134, 20447380.
22. Levick JR. Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum 1981, 24(12):1550-1560. 10.1002/art.1780241215, 7326067.
23. Wilkinson P, Jeremy R, Brooks FP, Hollander JL. The Mechanism of Hypoalbuminemia In Rheumatoid Arthritis. Ann Intern Med 1965, 63:109-114.
24. Ballantyne F. Myocardial ischemia and ambulatory monitoring. Ann Intern Med 1983, 99(6):880-881.
25. Niwa Y, Iio A, Niwa G, Sakane T, Tsunematsu T, Kanoh T. Serum albumin metabolism in rheumatic diseases: relationship to corticosteroids and peptic ulcer. J Clin Lab Immunol 1990, 31(1):11-16.
26. Wunder A, Muller-Ladner U, Stelzer EH, Funk J, Neumann E, Stehle G, Pap T, Sinn H, Gay S, Fiehn C. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol 2003, 170(9):4793-4801.
27. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, Tomlinson IM. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 2008, 21(5):283-288. 10.1093/protein/gzm067, 18387938.
28. Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 2006, 54(6):1856-1866. 10.1002/art.21827, 16736523.
29. Muller D, Karle A, Meissburger B, Hofig I, Stork R, Kontermann RE. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007, 282(17):12650-12660. 10.1074/jbc.M700820200, 17347147.
30. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002, 303(2):540-548. 10.1124/jpet.102.037002, 12388634.
31. Osborn BL, Sekut L, Corcoran M, Poortman C, Sturm B, Chen G, Mather D, Lin HL, Parry TJ. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol 2002, 456(1-3):149-158.
32. Evans L, Hughes M, Waters J, Cameron J, Dodsworth N, Tooth D, Greenfield A, Sleep D. The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae. Protein Expr Purif 2010, 73(2):113-124. 10.1016/j.pep.2010.05.009, 20546898.
33. Ikuta S, Chuang VT, Ishima Y, Nakajou K, Furukawa M, Watanabe H, Maruyama T, Otagiri M. Albumin fusion of thioredoxin--the production and evaluation of its biological activity for potential therapeutic applications. J Control Release 2010, 147(1):17-23. 10.1016/j.jconrel.2010.05.020, 20678999.
34. Griffiths MM, Eichwald EJ, Martin JH, Smith CB, DeWitt CW. Immunogenetic control of experimental type II collagen-induced arthritis. I. Susceptibility and resistance among inbred strains of rats. Arthritis Rheum 1981, 24(6):781-789.
35. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980, 283(5748):666-668. 10.1038/283666a0, 6153460.
36. Campbell IK, Roberts LJ, Wicks IP. Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis. Immunol Cell Biol 2003, 81(5):354-366. 10.1046/j.0818-9641.2003.01185.x, 12969323.
37. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002, 13(4-5):357-368.
38. Seckinger P, Klein-Nulend J, Alander C, Thompson RC, Dayer JM, Raisz LG. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol 1990, 145(12):4181-4184.
39. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996, 39(5):797-809. 10.1002/art.1780390513, 8639177.
40. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. Arthritis Rheum 2008, 58(2 Suppl):S110-122.
41. van den Berg WB, Joosten LA, Helsen M, van de Loo FA. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994, 95(2):237-243. 1534928, 8306498.
42. Williams RO, Marinova-Mutafchieva L, Feldmann M, Maini RN. Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy. J Immunol 2000, 165(12):7240-7245.
43. Campo GM, Avenoso A, Campo S, Ferlazzo AM, Altavilla D, Calatroni A. Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther 2003, 5(3):R122-131. 10.1186/ar748, 165044, 12723984.